1. Scrip
  2. >>Business

How Eisai Hopes To Expand In India

 
• By Anju Ghangurde

Japan's Eisai appears set for a significant step up in product introductions in India. Improving access to these medicines for patients in the largely self-pay market is at the fulcrum of its strategy, Dr Sanjit Singh Lamba, managing director of Eisai Pharmaceuticals India Pvt Ltd, tells Scrip. Newer options like a second brand approach may also be evaluated for certain new products to expand access and availability across the country.

Eisai Pharmaceuticals India Pvt. Ltd., which has received regulatory approval for its antiepileptic drug, Fycompa (perampanel hydrate), and for Lenvima (lenvatinib mesylate) in thyroid cancer in India, is working with the Indian government from the "pricing point of view" to facilitate access to these products.

Dr Sanjit Singh Lamba, managing director of Eisai Pharmaceuticals India Pvt Ltd, indicated that the company will look at patient assistance programs (PAP) for these products to ensure affordable access...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

More from Scrip

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.